New Partnership Forms to Harness AI for Alzheimer’s Research
Drawing in researchers in academia, pharma, and AI companies, a nascent consortium aims to speed up discoveries in complex diseases. Smaller AI projects report data at AD/PD.
Drawing in researchers in academia, pharma, and AI companies, a nascent consortium aims to speed up discoveries in complex diseases. Smaller AI projects report data at AD/PD.
Several tracers detect the low level of α-synuclein aggregates present in sporadic disease. None are ready for clinical use.
Among people vaccinated against shingles in Wales, there were 20 percent fewer dementia diagnoses over the next seven years.
In a head-to-head comparison, the two markers similarly predicted cognitive decline in healthy people. Still, using them sequentially might best identify who will benefit from therapy.
Ratio of two peptides in cerebrospinal fluid increases with age, a change accelerated by Alzheimer’s disease.
Donanemab prescriptions have been slow to ramp up, but demand is growing due to an easier dosing schedule than for lecanemab.
Healthy people who carry an autosomal-dominant AD mutation halved their odds of developing symptoms when they took gantenerumab for eight years.
Core structures of protofilaments from more diseases prompt an update to the family tree of tau filaments.
Scientists can now peek at pathology in people living with sporadic Parkinson’s disease. In pilot studies, several tracers light up the sparse aggregates in the substantia nigra of these patients. All the candidates still need tweaking, but the rapid progress suggests a reliable a-synuclein tracer is not far off.
New in last 7 days
Latest Comments